- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease — Recruiting • Neurology • NCT07227896.
- What is being tested: Foslevodopa/foscarbidopa (a continuous subcutaneous infusion therapy) is being evaluated for its effects on quality of life outcomes in adults with advanced Parkinson's disease, with earlier intervention timing than currently standard practice.
- Patient eligibility overview: The study recruits adult participants with advanced Parkinson's disease who meet specific clinical criteria; exact eligibility requirements should be confirmed with the trial protocol, but typically includes disease stage and symptom severity thresholds.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across…
- : * Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable * A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD) * Adult male or female between 18 and 80 years of age * Disease duration (time since diagnosis)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.